Aquestive Therapeutics (NASDAQ:AQST) Posts Earnings Results

Aquestive Therapeutics (NASDAQ:AQST) issued its quarterly earnings data on Monday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), Zacks reports. The company had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same quarter last year, the firm earned ($0.03) earnings per share.

Aquestive Therapeutics Trading Up 4.0 %

Shares of AQST traded up $0.19 during mid-day trading on Wednesday, hitting $4.95. 214,950 shares of the company traded hands, compared to its average volume of 1,747,141. The stock has a market capitalization of $450.75 million, a price-to-earnings ratio of -11.00 and a beta of 2.82. The business has a 50-day moving average of $4.90 and a 200 day moving average of $3.82. Aquestive Therapeutics has a one year low of $1.55 and a one year high of $6.23.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday. Finally, Leerink Partners lifted their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Aquestive Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $8.83.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.